Macmillan lends support to UK prostate cancer data project

News
Macmillan and Prostate Progress logos

Prostate Progress, a UK research programme led by Prostate Cancer Research (PCR) in partnership with the NHS, is expanding its reach through an alliance with Macmillan Cancer Support.

First launched in 2024, the project takes the form of a data platform that combines prostate cancer patient-reported experiences and clinical data derived from NHS health records, and aims to speed up the development of better tests, treatments and care, for example by connecting patients with clinical trials. It is supported by NHS England's Data for Research and Development programme, which was set up during the COVID-19 pandemic to make real-world healthcare data available to researchers.

A recruitment drive started in earnest in August of this year, and Prostate Progress is now open to anyone in the UK with a current or past prostate cancer diagnosis, aiming to reach up to 500,000 men. It has been championed by actor and broadcaster Sir Stephen Fry, who was diagnosed with prostate cancer in 2018 and has applauded its potential to achieve "enormous collective good."

Working with Macmillan, PCR will be able to tap into the network of more than 475,000 cancer patients supported by the organisation each year, helping the project to identify and "strengthen engagement" with people who are eligible to participate, particularly those from diverse and underserved communities.

"At Macmillan, we know that people living with cancer are the experts in their own lives, and when their experiences are heard alongside clinical data, we can build a far stronger case for change," said Macmillan's chief nursing officer, Claire Taylor.

"That’s why we’re pleased to partner with Prostate Cancer Research to expand the reach of Prostate Progress," she added. "Together, we’ll learn more about what it’s really like to live with prostate cancer, and make sure those insights shape better, fairer care for everyone living with cancer."

The two organisations will collaborate on the development of new research questions focused on improving early diagnosis, personalised care and reducing health inequalities, and try to identify "gaps, delays and variation" in prostate cancer pathways.

The alliance also plans to use patient-reported insights to inform advocacy, service design and policy development and explore ways to use patient experience and clinical data together to support more proactive and personalised care.

"Too often, healthcare systems only see part of the picture," said PCR's director of partnerships, Peter Harrison. "By combining clinical data with the experiences people share about living with cancer, we can gain a much deeper understanding of where the system is working well, where it is falling short, and what needs to change.

Around 600,000 men in the UK are living with or after a prostate cancer diagnosis – an increase of 100,000 since 2020 – with 68,000 new diagnoses each year. One in eight men in the UK will be diagnosed with prostate cancer in their lifetime, and for Black men, the risk doubles to one in four.